Cargando…

Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA

Slow responders to tuberculosis (TB) treatment in Virginia have prolonged treatment duration and consume more programmatic resources. Diabetes is an independent risk factor for slow response and low serum anti-TB drug concentrations. Thus, a statewide initiative of early therapeutic drug monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heysell, Scott K., Moore, Jane L., Staley, Debbie, Dodge, Denise, Houpt, Eric R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855970/ https://www.ncbi.nlm.nih.gov/pubmed/24349775 http://dx.doi.org/10.1155/2013/129723

Ejemplares similares

Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA
por: Alkabab, Yosra, et al.
Publicado: (2017)

Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
por: Heysell, Scott K., et al.
Publicado: (2010)

Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014
por: Heysell, Scott K., et al.
Publicado: (2015)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
por: Pienaar, Elsje, et al.
Publicado: (2018)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Mycobacterial infections in a large Virginia hospital, 2001-2009
por: Satyanarayana, Gowri, et al.
Publicado: (2011)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis in a Single Patient
por: Baffoe-Bonnie, Anthony, et al.
Publicado: (2019)

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
por: Agyemang, Nana, et al.
Publicado: (2023)

Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis
por: Chen, Suting, et al.
Publicado: (2017)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Validation of the FluoroType MTBDR Assay for Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates
por: Hillemann, Doris, et al.
Publicado: (2018)

Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge
por: Havlicek, Juliane, et al.
Publicado: (2018)

Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis
por: Sirous, Mehrandokht, et al.
Publicado: (2018)

Successful rapid oral desensitization for dual hypersensitivity to isoniazid and rifampin while treating central nervous system tuberculosis
por: Roy, Moni, et al.
Publicado: (2018)

Detecting rifampin and isoniazid resistance in Mycobacterium tuberculosis direct from patient sputum using an automated integrated system
por: Colman, Rebecca E., et al.
Publicado: (2022)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases
por: Vadwai, Viral, et al.
Publicado: (2012)

Multicenter Study of the Accuracy of the BD MAX Multidrug-resistant Tuberculosis Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated With Resistance to Rifampin and Isoniazid
por: Shah, Maunank, et al.
Publicado: (2020)

Effect of rifampin with bio-enhancer in the treatment of newly diagnosed sputum positive pulmonary tuberculosis patients: A double-center study
por: Nageswari, A.D., et al.
Publicado: (2018)

Evaluation of a High-Intensity Green Fluorescent Protein Fluorophage Method for Drug- Resistance Diagnosis in Tuberculosis for Isoniazid, Rifampin, and Streptomycin
por: Yu, Xia, et al.
Publicado: (2016)

A Rapid Assessing Method of Drug Susceptibility Using Flow Cytometry for Mycobacterium tuberculosis Isolates Resistant to Isoniazid, Rifampin, and Ethambutol
por: Lee, Sun-Kyoung, et al.
Publicado: (2022)

Response to Isoniazid-Resistant Tuberculosis in Homeless Shelters, Georgia, USA, 2015–2017
por: Holland, David P., et al.
Publicado: (2019)

Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method
por: Iwata, Kentaro, et al.
Publicado: (2020)

Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso
por: Miotto, Paolo, et al.
Publicado: (2009)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Hepatitis E Virus in Rabbits, Virginia, USA
por: Cossaboom, Caitlin M., et al.
Publicado: (2011)

Lyme Disease, Virginia, USA, 2000–2011
por: Brinkerhoff, R. Jory, et al.
Publicado: (2014)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

Performance Assessment of the BluePoint MycoID Plus Kit for Identification of Mycobacterium tuberculosis, Including Rifampin- and Isoniazid-resistant Isolates, and Nontuberculous Mycobacteria
por: Chien, Jung-Yien, et al.
Publicado: (2015)

Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection
por: Dasht Bozorg, Behnam, et al.
Publicado: (2019)

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
por: Kalokhe, Ameeta S., et al.
Publicado: (2012)

Theileria orientalis Ikeda Genotype in Cattle, Virginia, USA
por: Oakes, Vanessa J., et al.
Publicado: (2019)

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
por: Sam, I-Ching, et al.
Publicado: (2006)

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old
por: Kwara, Awewura, et al.
Publicado: (2018)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
por: Huang, Yu-Tsung, et al.
Publicado: (2018)

Rickettsia parkeri in Gulf Coast Ticks, Southeastern Virginia, USA
por: Wright, Chelsea L., et al.
Publicado: (2011)

Evaluating Geologic Sources of Arsenic in Well Water in Virginia (USA)
por: VanDerwerker, Tiffany, et al.
Publicado: (2018)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bjhfufqi5p80j27a6ssle5ff5f